Dosing: The key to precision plasma oncology,Plasma Processes and Polymers

当前位置： X-MOL 学术 › Plasma Processes Polym. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Dosing: The key to precision plasma oncology
Plasma Processes and Polymers ( IF 2.9 ) Pub Date : 2020-04-16 , DOI: 10.1002/ppap.201900178
Xiaofeng Dai ₁ , Zhifa Zhang ₁ , Jianying Zhang ₂ , Kostya (Ken) Ostrikov ₃

Affiliation

Cold atmospheric plasma (CAP) is an emerging oncotherapeutic approach with selectivity for cancer cells. It can induce different cell survival and death programs depending on the CAP dose, and it can function as a neo or adjuvant therapy against cancer. Establishing an evaluation system for precise CAP dosing is the key to make plasma therapy act alone or in combination with other therapeutic modalities for achieving desirable treatment responses. By classifying CAP-induced effects and associating them with the dosing of plasma-reactive agents, we identify opportunities for CAP to contribute to precision oncotherapy and discuss challenges en route to clinical applications. We emphasize the importance of dosing in plasma medicine and encourage cross-disciplinary collaborations to develop suitable dosing metrics.

中文翻译：

剂量：精准等离子肿瘤学的关键

冷大气等离子体 (CAP) 是一种新兴的肿瘤治疗方法，对癌细胞具有选择性。它可以根据 CAP 剂量诱导不同的细胞存活和死亡程序，并且可以作为抗癌的新疗法或辅助疗法。建立精确 CAP 剂量的评估系统是使血浆疗法单独或与其他治疗方式结合以实现理想治疗反应的关键。通过对 CAP 诱导的效应进行分类并将它们与血浆反应剂的剂量相关联，我们确定了 CAP 为精准肿瘤治疗做出贡献的机会，并讨论了临床应用过程中的挑战。我们强调血浆药物剂量的重要性，并鼓励跨学科合作开发合适的剂量指标。

更新日期：2020-04-16

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11